RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Acer Therapeutics ROCE 2024

Acer Therapeutics ROCE

1.47

Acer Therapeutics Dividend yield

Ticker

ACER

ISIN

US00444P1084

WKN

A2DYQV

In 2024, Acer Therapeutics's return on capital employed (ROCE) was 1.47, a -84.13% increase from the 9.25 ROCE in the previous year.

Acer Therapeutics Aktienanalyse

What does Acer Therapeutics do?

Acer Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel drugs for rare and life-threatening diseases. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts. The history of Acer Therapeutics began with an innovative strategy for rediscovering already approved drugs for new therapeutic applications. The company utilizes a "repurposing" technology, in which already approved drugs are reevaluated and further developed for the treatment of rare diseases. Acer Therapeutics' business model includes a combination of in-house research activities, strategic partnerships, and acquisitions. The company follows a portfolio strategy with a focus on rare diseases to develop a diversified pipeline of innovative medications. The various divisions of Acer Therapeutics focus on different therapeutic areas. Currently, the company is focused on the development of drugs for the treatment of rare anemia, severe lymphocytic leukemia, and narcolepsy. Acer Therapeutics' flagship product is EDSIVO, a medication for the treatment of arterial hypertension, a rare and life-threatening condition characterized by elevated blood pressure in the arteries. EDSIVO is currently approved in the United States and is under review in Europe. The company plans to further develop EDSIVO for the treatment of other rare diseases. Another important product of Acer Therapeutics is ACER-001, a medication for the treatment of the rare metabolic disorder urea cycle disorders. ACER-001 is an oral formulation of sodium phenylbutyrate and is intended to help patients regulate ammonia metabolism and alleviate symptoms. In recent years, Acer Therapeutics has also entered into several strategic partnerships and acquisitions to expand and strengthen its pipeline of rare diseases. In 2019, the company acquired biopharmaceutical specialist Celipheon, thereby expanding its portfolio to include drugs for the treatment of anemia and leukemia. Another important partner of Acer Therapeutics is Ultragenyx Pharmaceutical, a biopharmaceutical company specializing in the development of therapies for rare and ultra-rare diseases. The two companies have entered into a licensing agreement for ACER-001, in which Ultragenyx has exclusive rights for the commercialization of the medication in North America and Europe. Overall, Acer Therapeutics' business model and portfolio strategy have made it a key player in the rare disease sector. Through partnerships and acquisitions, it has expanded its pipeline and focused its research on various therapeutic areas. The company is currently in a growth phase and has the potential to bring more groundbreaking medications for rare diseases to the market in the future. Acer Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Acer Therapeutics's Return on Capital Employed (ROCE)

Acer Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Acer Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Acer Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Acer Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Acer Therapeutics Stock

What is the ROCE (Return on Capital Employed) of Acer Therapeutics this year?

The ROCE of Acer Therapeutics is 1.47 undefined this year.

How has the ROCE (Return on Capital Employed) of Acer Therapeutics developed compared to the previous year?

The ROCE of Acer Therapeutics has increased by -84.13% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Acer Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Acer Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Acer Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Acer Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Acer Therapeutics impact the company?

An increase in the ROCE of Acer Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Acer Therapeutics affect the company?

A decrease in ROCE of Acer Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Acer Therapeutics?

Some factors that can affect Acer Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Acer Therapeutics so important for investors?

The ROCE of Acer Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Acer Therapeutics take to improve the ROCE?

To improve the ROCE, Acer Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Acer Therapeutics pay?

Over the past 12 months, Acer Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acer Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Acer Therapeutics?

The current dividend yield of Acer Therapeutics is .

When does Acer Therapeutics pay dividends?

Acer Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acer Therapeutics?

Acer Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Acer Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acer Therapeutics located?

Acer Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acer Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acer Therapeutics from 5/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did Acer Therapeutics pay the last dividend?

The last dividend was paid out on 5/28/2024.

What was the dividend of Acer Therapeutics in the year 2023?

In the year 2023, Acer Therapeutics distributed 0 USD as dividends.

In which currency does Acer Therapeutics pay out the dividend?

The dividends of Acer Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Acer Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Acer Therapeutics

Our stock analysis for Acer Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acer Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.